Adagene’s ‘Masked’ Antibody Tech Gets a Powerful Endorsement from Third Arc

SAN DIEGO, CA – September 10, 2026

In the high-stakes world of oncology, a partner's capital is the ultimate vote of confidence. Adagene Inc. received just that this week, announcing that its partner, Third Arc Bio, has not only selected the first drug candidate from their collaboration but has also committed to bankrolling its entire clinical development. This move transforms a promising licensing deal into a deeply integrated partnership, providing a powerful strategic endorsement of Adagene’s proprietary “precision masking” technology and its potential to redefine safety in cancer immunotherapy.

The collaboration, initiated in late 2025, centers on developing a new class of cancer drugs known as masked CD3 T-cell engagers. By amending the agreement to have Third Arc Bio sponsor and fund the clinical journey, the partnership signals that the initial scientific progress has exceeded expectations, justifying a far deeper commitment.

A Partnership Forged in Precision

The amended agreement marks a significant strategic pivot, transitioning the collaboration into what the companies call an “integrated asset and technology partnership.” For Adagene, a clinical-stage biotech, this means a substantial portion of the immense financial risk associated with clinical trials is now lifted from its shoulders for this program. In return for Third Arc Bio’s expanded role, the total potential milestone payments due to Adagene have been increased, sweetening an already significant deal.

This commitment is made all the more meaningful by the pedigree of the partner. Third Arc Bio, launched in 2022 by Omega Funds, is steered by a team of industry veterans with a formidable track record. Its CEO, Peter Lebowitz, M.D., Ph.D., previously spent over a decade as the Global Head of Oncology R&D at Johnson & Johnson, where he was instrumental in bringing 13 new cancer drugs to market. The leadership team’s collective experience is credited with delivering 19 new medicines, giving their strategic decisions immense weight within the industry.

“We are pleased with the progress of this collaboration and the first lead selection,” said Dr. Lebowitz in the official announcement. “We look forward to delivering transformational therapies to patients through this highly productive partnership.” That a leader who has overseen the development of some of the world’s most successful cancer therapies is now putting his company’s resources behind Adagene’s technology is a validation that speaks louder than any press release.

The Strategic Validation of SAFEbody®

At the heart of this deepened alliance is Adagene’s SAFEbody® technology, a platform designed to solve one of the most persistent challenges in immuno-oncology: on-target, off-tumor toxicity. Many potent cancer therapies, including T-cell engagers, work by activating the immune system to attack tumor cells. The problem is that they often activate it everywhere, leading to severe side effects like Cytokine Release Syndrome (CRS) when healthy tissues expressing the same target are also attacked.

SAFEbody® technology addresses this by engineering antibodies with a molecular “mask.” This mask, a proprietary peptide, physically blocks the antibody’s binding site, rendering it inert as it circulates through the body. Only upon reaching the unique tumor microenvironment (TME) are specific enzymes present that can cleave the mask, unleashing the antibody’s full therapeutic power precisely where it’s needed. This conditional activation promises a much wider therapeutic window, allowing for potentially higher, more effective doses without the corresponding systemic toxicity.

While the candidate selected by Third Arc Bio is preclinical, the power of the SAFEbody® platform is already on display in Adagene’s own pipeline. Its lead asset, muzastotug (ADG126), is a masked anti-CTLA-4 antibody. In clinical trials for notoriously difficult-to-treat microsatellite stable (MSS) colorectal cancer, muzastotug, in combination with an anti-PD-1 therapy, has shown remarkable results. It achieved a confirmed objective response rate of 29% and an interim median overall survival of 19.4 months in a patient subset—a significant improvement over historical benchmarks. Crucially, it did so with a best-in-class safety profile, showing none of the severe colitis that has plagued earlier generations of anti-CTLA-4 therapies.

“We are proud to deepen our partnership with Third Arc Bio, a world class team with a track record of bringing innovative medicines including T cell engagers from discovery to commercialization for patients globally,” stated Peter Luo, Ph.D., CEO of Adagene.

De-Risking the Balance Sheet, Unlocking Value

For Adagene and its investors, the strategic implications of the deal are matched by its financial shrewdness. As of mid-2025, the company held $62.8 million in cash and equivalents. While it has been successfully managing its burn rate, the cost of running multiple clinical trials is immense. By offloading the development expenses for this new T-cell engager program to Third Arc Bio, Adagene de-risks a significant portion of its pipeline and preserves capital for its other wholly-owned assets, like muzastotug.

This partnership model is a core pillar of Adagene’s strategy. By licensing its platform to well-capitalized partners like Third Arc Bio and Sanofi, the company generates non-dilutive funding, gains external validation, and expands the applications of its technology far faster than it could alone. Furthermore, Adagene has astutely retained a no-cost option to co-develop and commercialize the resulting drug in key Asian markets, including Greater China, Singapore, and South Korea, ensuring it captures significant downstream value if the program succeeds.

This balanced approach of internal development and strategic partnering has resonated with market analysts, who hold a “Strong Buy” consensus on the company. The expanded Third Arc Bio deal reinforces this positive outlook, demonstrating management's ability to execute on a value-creating strategy that mitigates risk while maximizing the potential of its core technological asset.

The Next Frontier in the War on Cancer

The Adagene-Third Arc Bio collaboration is not happening in a vacuum. It sits at the forefront of a major industry trend: the push to make powerful T-cell engagers viable for solid tumors. While TCEs have seen great success in blood cancers, their systemic toxicity has limited their application in the far larger solid tumor market. Masked or conditionally active TCEs are seen by many as the key to unlocking this potential.

The market for these next-generation therapies is projected to grow to over $1.7 billion by 2036, and the field is heating up with competitors like CytomX Therapeutics and its Probody platform. However, the combination of Adagene’s clinically validated masking technology and Third Arc Bio’s deep expertise in T-cell biology and clinical execution creates a formidable contender. This partnership isn’t just about developing a single drug; it’s about building a franchise in one of the most promising new areas of oncology. If this lead candidate successfully navigates the clinic, it could pave the way for a new generation of safer, more effective cancer treatments for patients who currently have few options.